First Trust Advisors’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.84M Buy
186,552
+5,318
+3% +$114K ﹤0.01% 1726
2026
Q2
$3.33M Sell
181,234
-120,295
-40% -$1.94M ﹤0.01% 1783
2026
Q1
$5.9M Buy
301,529
+181,637
+152% +$5.39M ﹤0.01% 1347
2025
Q4
$3.73M Buy
+119,892
New +$3.29M ﹤0.01% 1576
2023
Q3
– Sell
-11,992
Closed -$285K – 2500
2023
Q2
$285K Buy
+11,992
New +$308K ﹤0.01% 2249

Other funds holding VRDN

First Trust Advisors's VRDN Position: Q3 2026 in Review

First Trust Advisors increased its Viridian Therapeutics (VRDN) stake by 2.9% in Q3 2026, buying an estimated $114K and bringing the position to 186,552 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

First Trust Advisors first reported a position in VRDN in Q2 2023 and has held it in 5 quarters since. The position peaked at $5.9M in Q1 2026. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • First Trust Advisors held 186,552 shares of Viridian Therapeutics worth $3.84M as of Q3 2026.
  • First Trust Advisors bought 5,318 Viridian Therapeutics shares in Q3 2026, an estimated $114K.
  • Viridian Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q3 2026, its #1726 holding.
  • First Trust Advisors first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 5 quarters since.
  • First Trust Advisors's Viridian Therapeutics position peaked at $5.9M in Q1 2026.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on First Trust Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.